Table 3.
Laboratory characteristics of patients with sickle cell disease and controls (median, min-max)
| SCD Patients (N = 35) | Controls (N = 19) | P value | |
|---|---|---|---|
| Age (years) | 13.5 ± 4.1 | 13.5 ± 3.5 | 0.557 |
| Gender (Boys/Girls) | 20/15 | 10/9 | 0.597 |
| TG (mg/dL) | 127 (58–246) | 89 (54–223) | 0.042 |
| TC (mg/dL) | 116 (76–170) | 167 (117–240) | 0.000 |
| HDL-C (mg/dL) | 28 (20–43) | 50 (32–82) | 0.000 |
| LDL-C (mg/dL) | 70 (44–106) | 106 (62–143) | 0.000 |
| VLDL-C (mg/dL) | 25 (12–49) | 18 (11–45) | 0.035 |
| Apo A1 (mg/dL) | 134 (94–378) | 198 (136–268) | 0.000 |
| Apo B (mg/dL) | 73 (54–202) | 82 (55–107) | 0.016 |
| LCAT (U/L) | 133 (8–457) | 285 (113–1190) | 0.441 |
| LDH (U/L) | 487 (251–1122) | 205 (122–293) | 0.000 |
| T. Bilirubin (mg/dL) | 1.7 (0.3–4.4) | 0.2 (0.1–0.6) | 0.000 |
| D. Bilirubin (mg/dL) | 0.4 (0.1–0.9) | 0.1 (0.0–0.1) | 0.000 |
| Hemin (mg/dL) | 2.80 (0.01–22.16) | 0.01 (0–0.27) | 0.000 |
| Serum Iron (μg/dL) | 81 (39–237) | 65 (14–143) | 0.385 |
| Ferritin (ng/mL) | 112 (35–1293) | 13 (6–46) | 0.000 |
| Uric acid (mg/dL) | 4.7 (3.4–8.3) | 4.0 (2.3–6.3) | 0.025 |
| SAA (mg/dL) | 1.14 (0.27–2.63) | 0.80 (0.27–1.69) | 0.041 |
| MPO (μg/L) | 76 (34–189) | 43 (29–56) | 0.000 |
| ALT (U/L) | 21 (10–86) | 12 (3–36) | 0.000 |
| GGT (U/L) | 14 (8–180) | 12 (3–24) | 0.023 |
SCD: sickle cell disease, TG: triglycerides, TC: total cholesterol, HDL-C: high-density lipoprotein cholesterol, LDL-C: low density lipoprotein cholesterol, VLDL-C: very low density lipoprotein cholesterol, Apo A1: apolipoprotein A1, Apo B: apolipoprotein B, FFA: free fatty acids, LCAT: lecithin acyl cholesterol transferase, LDH: lactate dehydrogenase, SAA: serum amyloid A, MPO: myeloperoxidase, ALT: alanine transaminase, GGT: gamma-glutamyl transferase